3-((5-oxo-5,6,7,8-tetrahydroquinazolin-2-yl)amino)benzonitrile | 1383718-50-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-((5-oxo-5,6,7,8-tetrahydroquinazolin-2-yl)amino)benzonitrile
• 英文别名: 3-[(5-oxo-7,8-dihydro-6H-quinazolin-2-yl)amino]benzonitrile
• CAS: 1383718-50-0
• 化学式: C₁₅H₁₂N₄O
• 分子量: 264.286
• InChiKey: POSMUJQZGLBEIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  78.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-[(二甲基氨基)亚甲基]-1,3-环己二酮 、 1-(3-cyanophenyl)guanidine 在 三乙胺 作用下， 以 乙醇 为溶剂， 以56%的产率得到3-((5-oxo-5,6,7,8-tetrahydroquinazolin-2-yl)amino)benzonitrile
  参考文献：
  名称：

  Discovery, synthesis, and structure–activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.049

文献信息

• [EN] INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE AND USES THEREOF<br/>[FR] INHIBITEURS DE GLUCOSE-6-PHOSPHATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS
  申请人：UNIV PRINCETON

  公开号：WO2021146543A1

  公开（公告）日：2021-07-22

  Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to inhibit the oxidative pentose phosphate pathway, e.g, to treat cancer, malaria, an autoimmune disease, an inflammatory condition or asthma.

  本文提供具有以下结构式的化合物，其中变量的值如本文所述。还提供了这些化合物的药物组合物，以及使用这些化合物抑制氧化戊糖磷酸途径的方法，例如治疗癌症、疟疾、自身免疫疾病、炎症症状或哮喘。
• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS GLUTAMATERGIQUES MÉTABOTROPES
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012085166A1

  公开（公告）日：2012-06-28

  The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  这项发明涉及杂环衍生物及其药用可接受的盐。该发明还涉及一种制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病是有用的。
• Discovery, synthesis, and structure–activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators
  作者：Holger Kubas、Udo Meyer、Bjoern Krueger、Mirko Hechenberger、Maksims Vanejevs、Ronalds Zemribo、Valerjans Kauss、Raisa Ambartsumova、Ilya Pyatkin、Alexey I. Polosukhin、Ulrich Abel

  DOI：10.1016/j.bmcl.2013.06.049

  日期：2013.8

  A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia. (c) 2013 Elsevier Ltd. All rights reserved.